Aumolertinib

Pipeline

Status by Indication[3][1]

Competition

Competitive Landscape

Non-Small Cell Lung CancerLung Cancer

449 competitors in Non-Small Cell Lung Cancer

#DrugCompanyPhaseTrials

1

Opdualag

Bristol-Myers Squibb

Phase 3

32

Cadonilimab

SShanghai Pharmaceuticals Holding Co., Ltd

Phase 3

63

Aumolertinib

Jiangsu Hansoh Pharmaceutical Co., Ltd.

Phase 3

44

Ivonescimab, Docetaxel

AAkeso

Phase 3

15

Remeron

OOrganon and Co

Preclinical

16

Valemetostat Tosylate

Daiichi Sankyo

Preclinical

17

Aqupla

Jiangsu Simcere Pharmaceutical Co., Ltd.

Preclinical

—8

Ftorafur

TThe First Affiliated Hospital with Nanjing Medical University

Preclinical

—9

Vibramycin

PPfizer's Upjohn has merged with Mylan to form Viatris Inc.

Preclinical

—10

Treatment

GSK

Preclinical

1Show 27 more competitors

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Timeline

Expected Milestones

Clinical

Trials by Indication[1]

Non-Small Cell Lung Cancer4 trials

A Study of HS-20117 Combined With Aumolertinib in Participants With Advanced Non-Squamous Non-Small Cell Lung Cancer

Recruiting·HHansoh BioMedical R&D Company·Phase 2/3·NCT06417008·1,080 enrolled

Efficacy of SRT as Salvage Therapy in Patients With Brain Oligo-progression of EGFR-mutant Non-small Cell Lung Cancer After Failure of the Third-generation EGFR-TKIs

Unknown status·SShanghai Cancer Hospital, China·Phase 2·NCT04519983·40 enrolled

Aumolertinib with or Without Chemotherapy As 1st Line Treatment in Locally Advanced or Metastatic Non-Small Cell Lung Cancer with Sensitizing EGFR Mutations

Active, not recruiting·Jiangsu Hansoh Pharmaceutical Co., Ltd.·Phase 3·NCT04923906·624 enrolled

Show 1 more trial

A Study of Aumolertinib in European Participants With Non-Small Cell Lung Cancer

Recruiting·Jiangsu Hansoh Pharmaceutical Co., Ltd.·Phase 1·NCT07130916·20 enrolled

Stage IB-IIIA NSCLC1 trial

Aumolertinib in EGFR-Mutant Resected Stage IB-IIIA NSCLC (AERESA).

Withdrawn·SSun Yat-sen University·Phase 2·NCT06227897

Adjuvant Therapy1 trial

Aumolertinib Adjuvant Therapy of Resectable Stage I EGFRm+ NSCLC With High-grade Patterns

Unknown status·BBaohui Han·Phase 2·NCT04922138·104 enrolled

Tics1 trial

An Open-Label, Single-Dose, Parallel-Group Study of the Pharmacokinetics and Safety of EQ143

Completed·EEQRx International, Inc.·Phase 1·NCT05199610·12 enrolled

Lung Cancer1 trial

Aumolertinib Versus Osimertinib As First-line Therapy for Patients with EGFR Mutated Locally Advanced or Metastatic Non-small-cell Lung Cancer

Not yet recruiting·PPeking Union Medical College Hospital·Phase 2·NCT06752408·316 enrolled

3 more indications

Neoadjuvant1 trial

Neoadjuvant Aumolertinib in Patients With AI-diagnosed EGFR-mutant High-risk Pulmonary Ground-glass Opacity.

Unknown status·TThe First Affiliated Hospital of Guangzhou Medical University·Phase 2·NCT05946460·22 enrolled

Oral1 trial

To Evaluate the Comparative Pharmacokinetics of Orally Administered EQ143 in Different Racial and Ethnic Populations

Completed·EEQRx, Inc.·Phase 1·NCT04969965·45 enrolled

Advanced or Metastatic NSCLC1 trial

A Study of SHR-A2009 Combined With Aumolertinib Versus Aumolertinib for First-line Treatment in EGFR-mutated, Advanced or Metastatic NSCLC

Recruiting·Suzhou Suncadia Biopharmaceuticals Co., Ltd.·Phase 3·NCT07183189·576 enrolled

Details

Drug Info

Related News